Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
40%(2 trials)

Phase Distribution

Ph phase_2
3
43%
Ph phase_4
3
43%
Ph phase_3
1
14%

Phase Distribution

0

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
3(42.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(5)
Other(2)

Detailed Status

Completed5
unknown2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (42.9%)
Phase 31 (14.3%)
Phase 43 (42.9%)

Trials by Status

completed571%
unknown229%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_3

hATG+CsA vs hATG+CsA+Eltrombopag for SAA

NCT02099747
completedphase_2

A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

NCT03025698
completedphase_4

Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT

NCT02677181
completedphase_2

Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia

NCT00065260
unknownphase_4

ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis

NCT04203108
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT02099747Phase 3

hATG+CsA vs hATG+CsA+Eltrombopag for SAA

Completed
NCT03025698Phase 2

A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

Completed
NCT02677181Phase 4

Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT

Completed
NCT00065260Phase 2

Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia

Completed
NCT04203108Phase 4

ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis

Unknown
NCT02404025Phase 2

Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects

Completed
NCT02838992Phase 4

ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7